| Factor Information | |
|---|---|
| Data ID | 10 |
| Factor | NT‐proBNP |
| Description | N/A |
| Biomarker | YES |
| Classification | E2 (physiological factor - biochemical index) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | To propose an accurate and simple system based on current guidelines for risk stratification in PAH‐CHD patients during 12‐ month follow‐up. |
| p Value | 0.01 |
| OR | 0.35 |
| Conclusion | 6-MWD and NT-proBNP predicted AEs independently for PAH-CHD patients. Simplified risk stratification system by taking these two parameters numerically provides accurate prognostic information in PAH-CHD patients. |
| Risk Factor | protective factor |
| CHD Type | |
|---|---|
| ID | 101 |
| CHD Type | isolated CHD |
| CHD Subtype | CHD with PAH |
| Reference | |
|---|---|
| PMID | 31419027 |
| Year | 2019 |
| Title | Guideline implementation and early risk assessment in pulmonary arterial hypertension associated with congenital heart disease: A retrospective cohort |
| Sample | ||
|---|---|---|
| Population | Adults | |
| Source | retrospective cohort study | |
| Region | Wuhan, China | |
| Method | reviewed | |
| Race | Asian | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | PAH-CHD with adverse event(Treatment) | PAH-CHD without adverse event(Control) |
| Number | 29 | 76 |
| Age | >18 years | >18 |
| Gender (Male: Female) | F/M | F/M |
| Marker Level | 1817.7 (440.7-2676.0) (pg/mL) | 251.9 (151.9-867.8) (pg/mL) |
